CHRISTIE BALLANTYNE to Cholesterol Ester Transfer Proteins
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Cholesterol Ester Transfer Proteins.
Connection Strength
2.050
-
Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. Am J Cardiol. 2013 Nov 01; 112(9):1287-92.
Score: 0.411
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.238
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
Score: 0.233
-
HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 05 02; 390(17):1622-1623.
Score: 0.216
-
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
Score: 0.133
-
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
Score: 0.129
-
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. J Med Genet. 2016 12; 53(12):835-845.
Score: 0.127
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
Score: 0.098
-
Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.
Score: 0.092
-
Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2008 Oct; 200(2):322-8.
Score: 0.070
-
Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study. J Stud Alcohol Drugs. 2007 Jul; 68(4):485-92.
Score: 0.067
-
Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis. 2007 Oct; 194(2):e131-40.
Score: 0.065
-
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
Score: 0.059
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.054
-
Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 12 06; 68(22):2488-2490.
Score: 0.032
-
Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. Circ Cardiovasc Genet. 2013 Aug; 6(4):391-9.
Score: 0.026